Overview

A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque Psoriasis

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study is designed to provide efficacy and safety data of several doses of AEB071 so that the optimal dose and treatment duration can be chosen for testing in later studies in patients with plaque psoriasis (with a disease severity such that systemic treatment is justified). The treatment free Follow-up Period is designed to provide additional safety data and information on disease recurrence after the last dose of the study drug.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals